Among 547 men who choose active surveillance, only two experienced tumor progression during the study, corresponding to an event-free survival at five years of 98.5%.
The study, “Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell-cycle risk score,” was published in the journal Future Medicine.
Prostate cancer is the most common cancer among men, but a great number of cases will remain dormant and not progress to cause significant disability or risk of mortality. In these cases, active surveillance — an approach that consists of actively monitoring the cancer to detect progression before starting any treatment — is an accepted alternative to treatments that can carry significant side effects.
Clinical exams to assess prostate cancer risk, however, can underestimate the number of patients who could benefit from active surveillance. Researchers estimate that only 40% to 50% of low-